PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025 Posted on September 4, 2025January 15, 2026 by edgover
PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025 Posted on September 4, 2025January 15, 2026 by edgover
A new treatment for dry AMD and tackling peanut allergies Posted on August 15, 2025January 15, 2026 by fowlerat
PulseSight doses first subject in Phase I trial of dry AMD/GA therapy Posted on July 8, 2025January 15, 2026 by edgover
First Patient Dosed in Phase 1 Clinical Trial of PulseSight Therapeutics’ Treatment for Dry AMD, GA Posted on July 7, 2025January 15, 2026 by edgover
PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy Posted on July 7, 2025January 15, 2026 by edgover
First patient dosed in trial for novel dry AMD treatment PST-611 Posted on July 7, 2025January 15, 2026 by edgover
PulseSight launches first-in-human trial of AMD gene therapy Posted on July 7, 2025January 21, 2026 by edgover
